Revertant and potentiating activity of lonidamine in patients with ovarian cancer previously treated with platinum.
- 1 October 1997
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 15 (10) , 3208-3213
- https://doi.org/10.1200/jco.1997.15.10.3208
Abstract
PURPOSELonidamine (LND) is an energolytic derivative of indazol-carboxylic acid that has been shown to enhance cisplatin (CDDP) activity in both sensitive (A2780) and resistant (A2780/Cp8) ovarian ...Keywords
This publication has 0 references indexed in Scilit: